Cyrus Biotechnology Integrates DNA/RNA Support into Its Rosetta-based Protein Design Platform

SEATTLE--(BUSINESS WIRE)-- Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, the most advanced computational protein design platform, is announcing the release of novel software capabilities to handle protein interactions with DNA & RNA as part of its Cyrus Bench^® platform.

“Proteins that interact directly with DNA and RNA are part of an increasing number of early discovery pipelines across the BioPharmaceutical industry, ranging from CRISPR proteins to enzymes for DNA synthesis and modification,” notes Cyrus CEO Dr. Lucas Nivon. “At Cyrus we can now accelerate discovery in these key new markets with the newly released DNA/RNA Rosetta protein design capabilities in Cyrus Bench.”

Rosetta software is the world leader in protein modeling and design, with features including homology modeling and design to improve both protein affinity and protein stability. Rosetta combines both physical and statistical/machine learning methods, and differs from all other commercially available modeling software in the breadth of both application and experimental validation. Proteins designed using Rosetta are in pre-clinical or clinical evaluation by companies such as Tocagen, PvP Bio, Sana and Lyell.

These new features in Cyrus Bench^® enable accelerated optimization and design of both tool compounds and therapeutic candidates, including polymerases, transcription factors, DNA modifying enzymes (e.g. CRISPRs), RNA modifying enzymes (e.g. isomerases) and other valuable compounds. These targets are critical to such fields as Therapeutics, Diagnostics, Agricultural Biotechnology and Biotechnology Tools.

These new software capabilities are available now to subscribers to Cyrus Bench^® and to new customers who subscribe to the Cyrus Bench^® suite of tools.

About Cyrus

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench^®, a SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench^® is based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 10 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

https://cyrusbio.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005228/en/